Investor Presentaiton

Consolidated Profit & Loss Statement Profit & Loss Statement (INR Million) Total Revenue Total Expenses (before finance cost and depreciation) Q3FY24 Q3FY23 Q2FY24 7,956 5,133 10,608 4,905 3,866 5,734 Earnings before interest, tax, depreciation and amortization (EBITDA) 3,051 1,267 4,874 EBITDA Margin* (%) 38.4% 24.7% 45.9% Finance cost Depreciation Profit before tax (PBT) Tax 46 38 42 442 415 436 2,563 814 4,396 436 191 706 Profit after tax (PAT) 2,127 623 3,690 PAT Margin (%) 26.7% 12.1% 34.8% Reported Earnings per share (EPS) INR Basic and Diluted 11.88 3.41 20.60 *includes other income Natco Pharma Limited - Earnings Presentation - Q3FY24 8

View entire presentation